Related references
Note: Only part of the references are listed.Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
Alexander Solms et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery
G. Erdoes et al.
ANAESTHESIA (2018)
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations
Stefan Willmann et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2018)
2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force
John U. Doherty et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
Ziad Hijazi et al.
LANCET (2016)
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
Emily C. O'Brien et al.
EUROPEAN HEART JOURNAL (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
Winnie W. Nelson et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2015)
Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation
Ophelia Q. P. Yin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
I. G. Girgis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Factors Associated With Major Bleeding Events
Shaun G. Goodman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts
Jonathan P. Piccini et al.
CIRCULATION (2013)
Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin A Systematic Review and Meta-analysis
Ida Ehlers Albertsen et al.
STROKE (2013)
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
Leif Friberg et al.
EUROPEAN HEART JOURNAL (2012)
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
Jonas Bjerring Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
Margaret C. Fang et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
Manesh R. Patel
AMERICAN HEART JOURNAL (2010)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Share Paper
